Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trialKohei Shitara, Tomasz Olesiński, Christian Caglevic et al.|The Lancet|2018Cited by 1.3k
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trialMichael Weller, Maciej M. Mrugała, Nicholas Butowski et al.|The Lancet Oncology|2017Cited by 1.1k
CTNI-54. A COMBINED ANALYSIS OF TWO RANDOMISED STUDIES EXPLORING THE IMPACT OF EXTENDED POST-RADIATION TEMOZOLOMIDE ON SURVIVAL OUTCOMES IN NEWLY DIAGNOSED GLIOBLASTOMALucy Gately, Carmen Balañá, Carlos Mesía et al.|Neuro-Oncology|2023Cited by 0
Abstract CT115: Phase 1b open-label, non-randomized, multi-center clinical trial of intratumoral IVX037 in combination with sintilimab (anti-PD1) in patients with advanced microsatellite stable (MSS) colorectal,gastroesophageal or ovarian cancerMark Wong, Jia Liu, Niall C. Tebbutt et al.|Cancer Research|2025Cited by 0